EWSR1-ERG fusion protein (EWS-ERG) (EWS-ERG)

The EWSR1-ERG fusion protein is a chimeric oncoprotein primarily associated with Ewing sarcoma, resulting from the t(21;22)(q22;q12) chromosomal translocation (Sorensen et al., 1994). It consists of the N-terminal transactivation domain of the EWSR1 protein fused to the C-terminal DNA-binding domain of the ERG transcription factor (UniProt P15502, P11308). This fusion creates a potent, aberrant transcription factor that dysregulates a wide array of genes critical for cell cycle progression, apoptosis resistance, and undifferentiated cellular states (Riggi et al., 2021). As a member of the ETS family of fusion proteins, it plays a central role in the pathogenesis of approximately 5-10% of Ewing sarcoma cases (National Cancer Institute). Therapeutic strategies focus on disrupting the protein's interaction with essential co-factors like RNA Helicase A (RHA) (Erkizan et al., 2009). Small molecule inhibitors like TK216 have been developed to interfere with these protein-protein interactions, showing promise in clinical settings for patients with EWS-fusion-driven malignancies (Oncternal Therapeutics).

Other names

EWSR1-ERGEWS-ERGt(21;22)(q22;q12) fusion proteinEWSR1/ERGEWS-ERG oncoprotein

The primary mechanism of action for emerging therapeutics like TK216 is the disruption of the protein-protein interaction between the EWSR1-ERG fusion protein and its transcriptional co-regulator, RNA Helicase A (RHA), which inhibits the protein's ability to drive oncogenic gene expression programs (Erkizan et al., 2009; Ludwig et al., 2021). Other agents like lurbinectedin and trabectedin work by displacing the fusion protein from its DNA binding sites or inducing its degradation (PMID: 31064780).